Results 141 to 150 of about 110,488 (256)

Precision therapies for genetic epilepsies in 2025: Promises and pitfalls

open access: yesEpilepsia Open, EarlyView.
Abstract By targeting the underlying etiology, precision therapies offer an exciting paradigm shift to improve the stagnant outcomes of drug‐resistant epilepsies, including developmental and epileptic encephalopathies. Unlike conventional antiseizure medications (ASMs) which only treat the symptoms (seizures) but have no effect on the underlying ...
Shuyu Wang   +3 more
wiley   +1 more source

Chronic sleep deprivation promotes drug‐resistant epilepsy via the BMAL1‐mTOR‐P‐gp axis

open access: yesEpilepsia Open, EarlyView.
Abstract Objective The interplay between chronic sleep deprivation and drug‐resistant epilepsy (DRE) has gained increasing attention. Brain and muscle Arnt‐like protein 1 (BMAL1), which is implicated in sleep disturbance, has an unclear role in DRE. We aimed to investigate the role of BMAL1 in sleep deprivation‐induced DRE. Methods A pentylenetetrazole
Xiaomeng Wang   +7 more
wiley   +1 more source

An Expanded Toolbox for Versatile Chemical Editing of Adeno-Associated Virus. [PDF]

open access: yesAngew Chem Int Ed Engl
Pham Q   +6 more
europepmc   +1 more source

Engineering of High-Yield Recombinant Adeno-Associated Virus Producer Plasmids. [PDF]

open access: yesBiotechnol J
Radukic MT   +10 more
europepmc   +1 more source

Nationwide audit of cervical cancer screening reveals unsatisfactory triage strategies and trends over time in incidence among cytology negative women

open access: yesInternational Journal of Cancer, EarlyView.
What's New? This population‐based cohort study aimed to demonstrate how annual audits of all aspects of the cervical cancer screening pathway can be performed using register national data with clinical validation to identify patterns of risk and inform program change.
Cecilia Kärrberg   +9 more
wiley   +1 more source

Generation of Allogeneic CAR‐T Circumvents Functional Deficits in Patient‐Derived Autologous Product for Glioblastoma

open access: yesInternational Journal of Cancer, EarlyView.
Clinical trials of chimeric antigen receptor T‐cell (CAR‐T) therapies in glioblastoma have shown limited clinical benefits. Whether this may be explained by the basal quality of CAR‐T products, which are currently generated using patient, autologous T‐cells, has been little explored.
Sabra K. Salim   +22 more
wiley   +1 more source

Home - About - Disclaimer - Privacy